Biacore held a technical tutorial at the Society of Biomolecular Screening meeting to demonstrate the value of its drug discovery platform in protein kinase studies
Biacore held a technical tutorial, including a presentation and a poster session, at the Society of Biomolecular Screening meeting. The presentation demonstrated the value of Biacore's drug discovery platform, BiacoreS51, in protein kinase studies. Protein kinases represent an extremely important class of therapeutic targets for a wide range of human diseases.
The complexity and diversity of kinase pathways, however, place high demands on the techniques needed to provide high quality information for drug development in this area.
Data included in the presentation illustrated the use of Biacore's SPR technology in a range of different kinase applications. BiacoreS51 was used, for example, to screen and evaluate kinase inhibitor lead compounds, identify inhibitor-binding sites on kinases and to compare inhibitor and substrate specificities for active/inactive kinases.
Julian Abery, vice president and gead of the pharmaceutical and biotechnology business unit at Biacore, commented, "The label-free, real time analysis provided by our SPR technology offers significant advantages over other techniques.
"Data obtained by SPR in these studies were highly consistent with those obtained using radiometric assays, but without the inconveniences of radioactive labeling.
"The ability to directly monitor compound binding to kinase or substrate, evaluate specificity and selectivity and determine kinetics, all from one instrument, makes BiacoreS51 ideal for the detailed characterisation of potential therapeutics directed against kinases."
